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In order to improve success rates in surgery of renal hyperparathyroidism, we evaluated intraop-
erative PTH (IOPTH) measurement utility.
Method: 86 patients underwent total parathyroidectomy with intramuscular presternal autotrans-
plantation from 04/2000 to 10/2009 and were followed for 26.5 months on average (prospective 
cohort). Patients were divided in secondary (SHPT) and tertiary hyperparathyroidism (THPT). SHPT 
group was composed by patients under dialysis treatment, THPT group included renal grafted ones. 
IOPTH (Elecsys-PTH-Immunoassay/Roche) was measured at anesthesia induction (IOPTH-0’) and 
20 minutes (IOPTH-20’) after parathyroidectomy.
Results: 80.2% (69/86) presented with 80% decrease or more in the IOPTH-20’ and all were cured. 
In 11/86 patients (12.7%), a lower IOPTH-20’ drop (70-79%) was observed, and 2 of them (18.1%) 
failed to cure. 6/86 (6.9%) patients presented IO-PTH-20’ decrease of less than 70%: two were cured, 
in three a supernumerary/ectopic parathyroid was found and removed, and in one of these six 
patients, surgery was finished after 4-gland excision and the patient failure to cure.
Conclusion: IOPTH-20’ decrease of 80% or more compared to IOPTH-0’ predicts cure in all renal 
patients throughout follow-up. A decay of less than 70% points to missed or hyperfunctioning 
supernumerary gland and is predictive of surgical failure in 66.6%. A marginal IOPTH drop of 70-79% 
leaves the decision whether or not surgery should be continued up to the experienced surgeon.
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INTRODUCTION
Secondary and tertiary hyperparathyroidism results 
from parathyroid gland hyperplasia and excess parathyroid 
hormone (PTH) secretion1. Despite recent advances in 
medical therapy, parathyroid surgical excision can be 
necessary in a considerable number of renal patients2. 
The best surgical approach for renal hyperparathyroidism 
is still debated, and controversy remains raising relevant 
questions regarding treatment election, since post-surgical 
recurrence or the risk of definitive hypoparathyroidism are 
to be avoided. Total parathyroidectomy with parathyroid 
tissue autotransplantation is a well-accepted technique for 
the management of these patients3-6. The surgical proce-
dure involves bilateral neck exploration, seeking for total 
removal of abnormal parathyroid tissue. Persistence and/
or recurrence indicate an inadequate resection of hyper-
functioning tissue. Reoperation is reported to be necessary 
for recurrent renal hyperparathyroidism in about 15% of 
cases, mostly due to the presence of supernumerary glan-
ds, inadequate initial parathyroidectomy, or the continued 
hyperplasia of remnant tissue7,8.
Since its introduction, intraoperative PTH moni-
toring (IO-PTH) has been performed in patients with 
primary hyperparathyroidism in several medical cen-
ters, becoming a well-recognized predictor of surgical 
success in in these patients9-13. By resorting to IO-PTH 
measurements, the surgeon can confirm total removal of 
the abnormal parathyroid glands, avoiding overlooking 
remaining or supernumerary hyperfunctioning glands. 
However, differently from patients with primary hyper-
parathyroidism, the role of IO-PTH monitoring in the 
surgical treatment of renal hyperparathyroidism is less 
established14. There is no standard definition of IO-PTH 
decay in renal hyperparathyroidism surgical treatment, 
since impaired renal function and delayed renal clearance 
of PTH can interfere in IO-PTH monitoring. Besides, few 
large series using IO-PTH monitoring in renal patients 
have been published14.
The aim of the present study was to evaluate the uti-
lity of intraoperative PTH monitoring in dialysis or kidney 
transplanted patients with secondary and tertiary hyper-
parathyroidism. Our aim was to define an IO-PTH cutoff 
value in order to avoid missed and/or supernumerary 
parathyroid glands, improving surgical success rates.
METHOD
Study design
This is a prospective study on a cohort of patients 
operated at a university referral center. All surgeries were 
performed by the same surgeon. This investigation was 
approved by Ethics Committee of our institution (approval 
No. CEP 886/00) and patients gave their informed consent 
prior to their inclusion in the study.
Patients
Eighty-six renal patients underwent total parathyroi-
dectomy with intramuscular presternal autotransplanta-
tion6 from April 2000 to October 2009, São Paulo, Brazil. 
Patients were followed in our institution and were referred 
to surgical treatment in face of: persistent hypercalcemia 
not responsive to medical interventions and/or persistent 
hyperphosphatemia despite the continued use of dietary 
phosphorus restriction and phosphate-binding agents, 
symptoms as intractable pruritus, severe bone pain, frac-
tures or high risk of fracture, skeletal deformities, extra 
skeletal calcifications, development of calciphylaxis and 
radiographic evidences of renal osteodystrophy.
They were divided in secondary and tertiary hyper-
parathyroidism groups. Secondary hyperparathyroidism is 
characterized as an acquired disorder seen in end-stage 
renal disease, in which the uremic state presents a con-
tinuous stimulus to the parathyroid glands. We included 
in the SHPT group, patients under dialysis treatment who 
presented severe hyperparathyroidism with normal or high 
serum calcium levels. Tertiary hyperparathyroidism group 
was composed by renal patients with kidney transplant 
with nonsuppressible parathyroid hyperplasia, with persis-
tent increased intact PTH levels and hypercalcemia even 
after restoration of normal renal function. Hypercalcemia 
after kidney transplantation is usually due to hyperpara-
thyroidism that persists from the preceding chronic kidney 
disease period15.
Serum ionized calcium (iCa), phosphorus (P), 
alkaline phosphatase (AP), and intact parathyroid hor-
mone (iPTH) were measured before parathyroidectomy 
(Table 1) and yearly after surgery in all patients from 
both groups.
Table 1. Patient demographic characteristics.
SHPT THPT
N 52 34
Age (years) 42.9 (14-64) 43.5 (24-63)
Female/male 29/23 19/15
Years in dialysis 7.4 (0.75-15) 6 (0.5-13)
Years of renal graft - 2.8 (0.1-5.3)
Follow-up (months) 27.8 (6-65) 24.5 (6-67)
Data on average and range (parenthesis).
Surgical cure was defined as restoration of serum 
calcium and iPTH levels as expected for each renal func-
tion stage, throughout the first 6 months after surgery15. 
Recurrence after surgery was defined when high levels 
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of iPTH were observed throughout late post-operative 
follow-up (1 year after surgical procedure) that failed 
to respond to medical/pharmacological management. 
Definitive hypoparathyroidism was described when PTH 
measurements under 10 pg/mL endures 1 year after para-
thyroidectomy, with normal or low serum calcium levels 
under vitamin D and oral calcium replacement.
Methods
Total parathyroidectomy with intramuscular pres-
ternal autotransplantation6 was performed in 86 patients 
from April 2000 to October 2009. Patients were evaluated 
throughout a 26.5-month follow up on average (range 
6-67 months).
Intra-operative PTH (IO-PTH) was performed in 
attempt to confirm total removal of the parathyroid glands, 
so as to avoid overlooking remaining or supernumerary 
hyperfunctioning glands. IO-PTH was measured by 
resorting to the Elecsys PTH Immunoassay (Elecsys 1010 
System, Roche, Mannheim, Germany). The time required 
to carry out the assay is 9 minutes and reference values 
are 10-70 pg/mL. Peripheral venous blood sample (4.0 mL) 
was obtained immediately after induction of anesthesia 
and 20 minutes after removal of all parathyroid glands12,13.
Phosphorus, total alkaline phosphatase and cre-
atinine were measured by means of standard automatic 
assays (Hitachi 912, Roche). Serum ionized calcium was 
measured by using an ion-specific electrode (AVL 9180 
Electrolyte Analyzer, Roswell, Georgia, USA). Parathyroid 
hormone was measured by immunometric assay (Immulite, 
DPC, MedLab).
RESULTS
Overall, 86 patients underwent total parathyroidec-
tomy with presternal intramuscular autotransplantation 
with IO-PTH monitoring. Patients were evaluated in a 
prospective way in an average follow-up of 26.5 months 
(ranging from 6 to 67 months). There were 52 patients in 
the SHPT group and 34 in THPT group. Patients from SHPT 
group presented an average of 7.4 years under dialysis 
treatment before parathyroidectomy, and THPT group 
comprised patients who had undergone dialysis treatment 
for an average of 6 years before receiving a kidney graft, 
with an average of 2.8 years of functional renal graft before 
parathyroidectomy. Patient demographic characteristics are 
depicted in Table 1 and patient pre-operative biochemical 
data are depicted in Table 2.
Regarding surgical findings, at least four parathyroid 
glands were identified and excised in all 86 patients, and 
supernumerary glands were found in three (the 5th para-
thyroid was located in the cervical region in two patients 
and in the thymus in one).
Patients under dialysis treatment, who were cured 
after surgery, presented IO-PTH basal levels of 1591.5 pg/
mL on average, and IO-PTH 20 minutes after total para-
thyroidectomy of 208.9 pg/mL on average, with 86% de-
crease. Among renal-grafted cured patients, basal IO-PTH 
was 540 pg/mL on average, and 65 pg/mL on average, 
20 minutes after total parathyroidectomy, with a 87.3% 
decrease on average (Table 3).
Table 2. Patient pre-operative laboratory data.
SHPT (N = 52) THPT (N = 34)
iCa 1.38 mmol/L (1.19-1.83) 1.59 mmol/L (1.42-1.75)
iPTH 1682.1 pg/mL (516-2500) 440.9 pg/mL (109-1758)
P 6.5 mg/dL (4.1-11.8) 2.8 mg/dL (1.9-6.3)
AP 603.2 U/L (150-1639) 289.9 U/L (66-1304)
Cr - 1.7 mg/dL (1-9.2)
SHPT: Secondary hyperparathyroidism; THPT: Tertiary hyperpara-
thyroidism, iCa: Serum ionized calcium, P: Phosphorus; AP: Alka-
line phosphatase; iPTH: Intact parathyroid hormone. Reference 
values: iCa: 1.11-1.40 mmol/L; P:2.3-4.6 mg/dL; AP: 35-129 U/L; 
iPTH: 10-65 pg/mL. Data on average and range (parenthesis).
Table 3. Intra-operative PTH decay in cured patients.
SHPT THPT
IO-PTH 1591.5 pg/mL (318-4659) 540 pg/mL (120-2515)
IO-PTH 20’ 208.9 pg/mL (29-823) 65 pg/mL (13-329)
% decrease 86% (67.8-93.5) 87.3% (72.6-96.4)
Post-op iCa 1.22 mmol/L (0.97-1.38) 1.20 mmol/L (1.04-1.35)
Post-op iPTH 76.4 pg/mL (5-497) 60.8 pg/mL (17-142)
Follow up (months) 27.8 (6-67) 25 (6-67)
IO-PTH 0’: Intra-operative PTH in anesthesia induction; IO-PTH 20’: 
Intra-operative PTH 20 minutes after total parathyroidectomy; SHPT: 
Secondary hyperparathyroidism; THPT: Tertiary hyperparathyroidism 
iCa: Serum ionized calcium, iPTH: Intact parathyroid hormone; Post-op 
iCa and iPTH: Post-operative measurements of iCa and PTH. Data on 
average and range (parenthesis).
Overall, 69 patients (80.2%) presented 80% decrease 
or more in IO-PTH levels, and all patients were cured 
(Graph 1). Eleven patients (12.7%) presented a drop of 
70-79%, and among them, two patients failed to cure 
(IO-PTH decrease of 76.9% and 77.2%) (Table 4, Graph 1). 
IO-PTH prevented surgical failure in three patients, in 
whom a 58.5%, 51.8% and 62% IO-PTH drop was con-
sidered insufficient. Surgical exploration was continued 
and a supernumerary cervical parathyroid gland was 
removed in two and supernumerary ectopic parathyroid 
in the thymus was resected in one (Table 5, Graph 1). 
One patient presented IO-PTH drop of 67.4% (Table 5, 
patient 4). This drop was considered sufficient and sur-
gery was finished after excision of four parathyroid 
glands. Post-operative PTH levels remained high in the 
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early post-operative follow-up, and patient was conside-
red not cured (Table 5, patient 4).
higher incidence of supernumerary/ectopic parathyroid 
glands in renal hyperparathyroidism7,8, point to IO-PTH 
measurement as an interesting tool in an attempt to avoid 
surgical failure.
Differences between SHPT and THPT patients might 
be pointed out regarding to IO-PTH decay profile: patients 
under dialysis treatment may present a slower IO-PTH 
decay compared to kidney-grafted ones, in which renal 
function is restored. Moreover, THPT patients resemble 
primary hyperparathyroidism patients, with hypercalcemia 
and normal renal function. However, THPT is a multi-
glandular disease (in opposition to uniglandular primary 
hyperparathyroidism typical disease), requiring different 
surgical approach, probably interfering to IO-PTH kinect 
analysis. That coupled with the difficulty to assume 
completely normal renal function years after kidney-graft 
transplantation, turns THPT more similar to SHPT than to 
primary hyperparathyroidism. Due to the increased iPTH 
half-life in renal failure patients, a 20-minutes IO-PTH 
measurement was chosen, a delayed measurement in 
comparison to the 10-minutes IO-PTH measurement 
established in primary hyperparathyroidism. Thereafter, 
despite of potential differences among SHPT and THPT 
patients, data were studied coupling both groups.
A few studies with small series and/or limited 
follow-up evaluating IO-PTH percentile decrease in renal 
population have been published8,13,14,22. Some authors 
have observed IO-PTH decay of 50 to 60% at 10 to 20 
minutes after parathyroidectomy as a reliable predictor 
of postoperative cure23-25. Other authors expected more 
than 80% decay in IO-PTH measurements 15 minutes 
after parathyroidectomy in order to assure surgical cure26. 
Our previous experience showed that a decrease of 70% 
20 minutes after parathyroidectomy indicates a successful 
surgical procedure13.
In this study, IO-PTH decay of 80% or more 20 
minutes after parathyroidectomy assured surgical cure in 
all patients. Overall, 69 (80.2%) patients presented IO-PTH 
decay of 80% or more, and all were cured. Six patients 
Graph 1. IO-PTH percent decrease and surgical outcome.
Table 4. Patients with 70-79% IO-PTH decrease who failure to cure.
IO-PTH 0’ IO-PTH 20’ Decrease 6 months post-op iCa PTH 20 months post-op iCa PTH
Patient 1 2481 pg/mL 573 pg/mL 76.9% 1.34 mmol/L 429 pg/mL 1.22 mmol/L 810 pg/mL
Patient 2 553 pg/mL 126 pg/mL 77.2% 1.60 mmol/L 179 pg/mL -
Reference values: iCa: 1.11-1.40 mmol/L; iPTH: 10-65 pg/mL.
Table 5. Patients with IO-PTH decrease less than 70%.
Pat IO-PTH 0’ IO-PTH 20’ % Surgical findings 6 mths post-op iCa PTH 20 mths post-op iCa PTH
1 1913 pg/mL 782 pg/mL 58.5% 5th PTX - -
2 1295 pg/mL 624 pg/mL 51.8% 5th PTX (thymus) - -
3 327 pg/mL 124 pg/mL 62% 5th PTX - -
4 860 pg/mL 280 pg/mL 67.4% Surgery finished after excision of 4 glands 1.26 605 pg/mL 1.24 1320 pg/mL
Pat: Patient; %: Percent decrease; mths: Months; 5th PTX: Supernumerary parathyroid. Reference values: iCa: 1.11-1.40 mmol/L; iPTH: 10-65 pg/mL.
Definitive hypoparathyroidism was observed in 
two patients, one in each group (2.3% among overall 
patients).
DISCUSSION
The rapid intraoperative determination of intact 
parathyroid hormone has become widely established in 
primary hyperparathyroidism surgical treatment, in which 
the removal of all hyperfunctioning parathyroid tissue 
is confirmed by a prompt decline in circulating iPTH 
within 5 to 10 minutes4,12,13,16-19. The intraoperative decay 
of circulating iPTH in renal patients is reproducible but 
markedly slower than in the patients with normal renal 
function. This is in accordance with the increased half-life 
of iPTH in renal failure (6.6 minutes versus 2.2 minutes)20. 
Studies with rapid intraoperative PTH measurement in 
secondary hyperparathyroidism demonstrated a stepwise 
decrease in circulating iPTH corresponding to sequential 
gland resection12,21; and those findings together with a 
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(6.9%) presented less than 70% decay in IO-PTH, and 
among them, four (66.6%) presented a supernumerary/
ectopic parathyroid removed (three of them) or remained 
not cured (one patient).
Taking into account these results, we conclude that 
80% decay or more in IO-PTH measurement 20 minutes 
after total removal of hypersecretory parathyroid tissue is 
expected and predicts 100% of cure. Moreover, IO-PTH 
decay under 70% is associated with 66.6% of surgical 
failure, most of which associated with a supernumerary/
ectopic parathyroid gland.
Special concerns have to be raised about the “margi-
nal” IO-PTH drop - between 70% to 79% - observed in 11 
patients (12.7%), since two patients among them (18.1%) 
failed to cure. Particular questions remain unsolved: how 
can the surgeon recognize these patients? To what extent 
should surgery continue in the search for further hyperse-
cretory glands? Those questions remain unanswered, and 
it is up to the experienced surgeon to point out when and 
how to conclude the surgical procedure, based on patient 
clinical aspects and ongoing surgical findings.
Limitations of this study are related to the heteroge-
neous characteristics of renal patients with their particular 
clinical and laboratory findings, and considering them 
as a group presents a real challenge. Another limitation 
relates to the severity of our patients: the marked illness 
and long-lasting renal condition make them a special 
group whose outcome would not be expected in ordinary 
patients with renal chronic disease. In addition, levels of 
25OH vitamin D were not available.
CONCLUSION
A decrease of IO-PTH of 80% or more from preope-
rative baseline predicts cure in all renal patients throughout 
follow-up. IO-PTH decay under 70% is in agreement with 
a missed or hyperfunctioning supernumerary gland and is 
predictive of surgical failure in 66.6%. The marginal IO-PTH 
drop of 70-79% leads the decision whether or not the sur-
gery should be continued up to the experienced surgeon.
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